RCT | Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after auto-SCT in patients with multiple myeloma

Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)

News Release: Triple-drug therapy for post-transplant management of multiple myeloma – University of Chicago Medical Center